NovaBay Pharmaceuticals Inc. (NBY)’s Financial Results Comparing With Intellia Therapeutics Inc. (NASDAQ:NTLA)

NovaBay Pharmaceuticals Inc. (NYSEAMERICAN:NBY) and Intellia Therapeutics Inc. (NASDAQ:NTLA) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NovaBay Pharmaceuticals Inc. 12.51M 1.42 6.54M 0.55 2.53
Intellia Therapeutics Inc. 30.43M 24.05 85.34M -2.16 0.00

Table 1 demonstrates NovaBay Pharmaceuticals Inc. and Intellia Therapeutics Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of NovaBay Pharmaceuticals Inc. and Intellia Therapeutics Inc.

Net Margins Return on Equity Return on Assets
NovaBay Pharmaceuticals Inc. -52.28% -71.9% -39%
Intellia Therapeutics Inc. -280.45% -30.6% -25%

Liquidity

The current Quick Ratio of NovaBay Pharmaceuticals Inc. is 2.7 while its Current Ratio is 2.8. Meanwhile, Intellia Therapeutics Inc. has a Current Ratio of 8 while its Quick Ratio is 8. Intellia Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than NovaBay Pharmaceuticals Inc.

Insider and Institutional Ownership

The shares of both NovaBay Pharmaceuticals Inc. and Intellia Therapeutics Inc. are owned by institutional investors at 1% and 74.6% respectively. NovaBay Pharmaceuticals Inc.’s share owned by insiders are 25.78%. Competitively, Intellia Therapeutics Inc. has 24.01% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NovaBay Pharmaceuticals Inc. -6.67% -25.69% 12.91% -17.65% -59.94% 81.18%
Intellia Therapeutics Inc. 15.53% 17.33% -2.93% -44.98% -34.45% 21.54%

For the past year NovaBay Pharmaceuticals Inc. has stronger performance than Intellia Therapeutics Inc.

Summary

NovaBay Pharmaceuticals Inc. beats Intellia Therapeutics Inc. on 6 of the 11 factors.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. Intellia Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.